Semaglutide
GLP-1 analogue
Semaglutide is a lipid-modified GLP-1 receptor agonist. Its reference identity includes a non-standard amino acid and a side-chain modification, so an ordinary peptide sequence alone would describe the wrong molecule.
Reviewed September 2026
- Residues
- 31. verified: 31 main-chain residues, including Aib; lipid/linker moieties are not counted as additional main-chain residues.
- Average mass
- 4,113.58 Da. verified: Sponsor-label molecular weight for semaglutide, C187H291N45O59, including its covalent modifications. Average molecular mass, not monoisotopic mass. Excludes unlisted counterions and formulation excipients; not an Aminos lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 31 |
|---|---|
| Average mass | 4,113.58 Da |
| pI | Not established |
| Aliases | GLP-1 analogue |
|---|---|
| Research area | Metabolic |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Semaglutide: GLP-1(7–37)-based chain with Aib8, Arg34 and Lys26-linked C18 diacid/spacer (GLP-1 numbering); reference molecule, not sodium or acetate salt. Reference only, not a sold-lot measurement.
- Residues: 31 (verified). 31 main-chain residues, including Aib; lipid/linker moieties are not counted as additional main-chain residues. Residues source 1 Residues source 2 Residues source 3
- Average mass: 4,113.58 Da (verified). Sponsor-label molecular weight for semaglutide, C187H291N45O59, including its covalent modifications. Average molecular mass, not monoisotopic mass. Excludes unlisted counterions and formulation excipients; not an Aminos lot measurement. Average mass source 1 Average mass source 2
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Semaglutide. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Semaglutide
Identity and context
The discovery paper identifies two substitutions relative to human GLP-1, including Aib, and derivatization at lysine 26. The linker and fatty-acid group were part of the design used to change albumin binding and exposure. These features distinguish semaglutide from native GLP-1 and from other incretin analogues.
Reference classification
Modified peptide. The linked catalogue product is Semaglutide. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Request the complete modified structure, chemical form and lot-specific analytical identification. A mass generated from a standard one-letter sequence would omit chemistry that is essential to this identity.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | Lau and colleagues tested candidate structures for receptor activity and albumin affinity, then evaluated pharmacokinetics in experimental animals. This is a useful primary source for how semaglutide was designed. Its development-stage statements describe the time of publication, not a current regulatory assessment. | Source context |
| What cannot be inferred | Receptor pharmacology and studies of defined pharmaceutical preparations do not authenticate the contents of a separately supplied research product. Neither those studies nor this reference establish the purity, stability or clinical suitability of an Aminos lot. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Discovery of the Once-Weekly GLP-1 Analogue SemaglutidePrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.